A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

Jesse L. Goodman, Daniel Weisdorf, Drew J. Winston, Winston G. ho, Ronald A. Greenfield, Pranatharthi H. Chandrasekar, Barry Fox, Herbert Kaizer, Richard K. Shadduck, Thomas C. Shea, Patrick Stiff, David J. Friedman, William G. Powderly, Jeffrey L. Silber, Harold Horowitz, Alan Lichtin, Steven N. Wolff, Kenneth F. Mangan, Samuel M. Silver, Gene GilbertDonald Buell

Research output: Contribution to journalArticlepeer-review

1077 Scopus citations


Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow transplantation. We performed a doubleblind, randomized, multicenter trial in which patients receiving bone marrow transplants were randomly assigned to receive placebo or fluconazole (400 mg daily). Fluconazole or placebo was administered prophylactically from the start of the conditioning regimen until the neutrophil count returned to 1000 per microliter, toxicity was suspected, or a systemic fungal infection was suspected or proved. By the end of the treatment period, 67.2 percent of the 177 patients assigned to placebo had a positive fungal culture of specimens from any site, as compared with 29.6 percent of the 179 patients assigned to fluconazole. Among these, superficial infections were diagnosed in 33.3 percent of the patients receiving placebo and in 8.4 percent of the patients receiving fluconazole (P<0.001). Systemic fungal infections occurred in 28 patients who received placebo as compared with 5 who received fluconazole (15.8 percent vs. 2.8 percent, P<0.001). Fluconazole prevented infection with all strains of candida except Candida krusei. Fluconazole was well tolerated, although patients who received it had a higher mean increase in alanine aminotransferase levels than patients who received placebo. Although there was no significant difference in overall mortality between the groups, fewer deaths were ascribed to acute systemic fungal infections in the group receiving fluconazole than in the group receiving placebo (1 of 179 vs. 10 of 177, P<0.001). Prophylactic administration of fluconazole to recipients of bone marrow transplants reduces the incidence of both systemic and superficial fungal infections. (N Engl J Med 1992;326:845–51.).

Original languageEnglish
Pages (from-to)845-851
Number of pages7
JournalNew England Journal of Medicine
Issue number13
StatePublished - Mar 26 1992


Dive into the research topics of 'A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation'. Together they form a unique fingerprint.

Cite this